NASDAQ:ALBO
Delisted
Albireo Pharma Inc Stock News
$44.15
+0 (+0%)
At Close: May 26, 2023
Is Albireo Pharma (ALBO) Outperforming Other Medical Stocks This Year?
11:18am, Thursday, 11'th Aug 2022
Here is how Albireo Pharma (ALBO) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Has Albireo Pharma (ALBO) Outpaced Other Medical Stocks This Year?
10:49am, Monday, 25'th Jul 2022
Here is how Albireo Pharma (ALBO) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.
Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation
03:50pm, Friday, 22'nd Jul 2022
Albireo promotes international sales of its approved product Bylvay for the treatment of the extremely rare and orphan disease PFIC. Investors do not yet appreciate the full potential of Bylvay, which
Albireo to Present at the William Blair Biotech Focus Conference 2022
08:00am, Thursday, 30'th Jun 2022
BOSTON, June 30, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced participation at the William Blair Bi
Albireo to Present New Data at the 54th Annual Meeting of ESPGHAN
08:30am, Tuesday, 07'th Jun 2022
– Four abstracts accepted of Phase 3 data from PEDFIC 1 and PEDFIC 2 trials of Bylvay™ (odevixibat)
Albireo to Participate at Upcoming Investor Conferences
04:30pm, Thursday, 02'nd Jun 2022
BOSTON, June 02, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief
Albireo to Participate in the H.C. Wainwright Global Investment Conference 2022
04:30pm, Thursday, 19'th May 2022
BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced participation in the H.C. Wainwright G
Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q1 2022 Results - Earnings Call Transcript
10:59pm, Monday, 16'th May 2022
Albireo Pharma, Inc. (NASDAQ:ALBO ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Hans Vitzthum - Managing Director-LifeSci Advisors, LLC Ron Cooper - President & Chief
Albireo Pharma (ALBO) Reports Q1 Loss, Lags Revenue Estimates
06:48pm, Monday, 16'th May 2022
Albireo Pharma (ALBO) delivered earnings and revenue surprises of -8.42% and 12.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Albireo to Report Q1 2022 Financial Results on May 16
08:30am, Monday, 09'th May 2022
Conference call and webcast to be held at 4:30 pm ET Conference call and webcast to be held at 4:30 pm ET
Albireo: A Speculative Play With Upside
02:06pm, Tuesday, 03'rd May 2022
The lead medicine (Bylvay) is already approved to treat an orphan disease known as progressive familial intrahepatic cholestasis. Leveraging a prudent growth strategy, Albireo is aggressively expandin
Albireo Pharma''s (ALBO) CEO Ron Cooper on Q4 2021 Results - Earnings Call Transcript
08:59pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Albireo Pharma, Inc. 2021 Q4 - Results - Earnings Call Presentation
05:26pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Albireo Pharma GAAP EPS of -$0.57, revenue of $32.52M
01:41pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Albireo Pharma press release (ALBO): Q4 GAAP EPS of -$0.57.Revenue of $32.52M (vs $2.72M in Q420).
Albireo Reports Q4 and Year-End 2021 Financial Results and Business Update
01:30pm, Tuesday, 01'st Mar 2022 GlobeNewswire
BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2021.
